BridgeBio Pharma Pre-Tax Income 2018-2024 | BBIO

BridgeBio Pharma pre-tax income for the twelve months ending June 30, 2024 was $-0.462B, a 21% decline year-over-year.

  • BridgeBio Pharma annual pre-tax income for 2023 was $-0.653B, a 34.79% increase from 2022.
  • BridgeBio Pharma annual pre-tax income for 2022 was $-0.485B, a 17.36% decline from 2021.
  • BridgeBio Pharma annual pre-tax income for 2021 was $-0.586B, a 16.02% increase from 2020.

BridgeBio Pharma Pre-Tax Income 2018-2024 | BBIO

  • BridgeBio Pharma annual pre-tax income for 2023 was $-0.653B, a 34.79% increase from 2022.
  • BridgeBio Pharma annual pre-tax income for 2022 was $-0.485B, a 17.36% decline from 2021.
  • BridgeBio Pharma annual pre-tax income for 2021 was $-0.586B, a 16.02% increase from 2020.
Related Stocks
Company NameMarket
Cap
Teva Pharmaceutical Industries (TEVA)$20.1B
Dr Reddy's Laboratories (RDY)$13.1B
Bausch Health Cos (BHC)$3B
Amphastar Pharmaceuticals (AMPH)$2.4B
Supernus Pharmaceuticals (SUPN)$1.8B
Taysha Gene Therapies (TSHA)$449M
Personalis (PSNL)$315M
Assembly Biosciences (ASMB)$117M
Acasti Pharma (ACST)$28M
Sol-Gel Technologies (SLGL)$20M
Evoke Pharma (EVOK)$4M
Teligent (TLGT)$0M